Goodwin has strong expertise in ERISA and executive compensation, offering experience to advising clients on the full spectrum of compensation and benefits matters. Co-chaired by Patrick Menasco in Washington DC, and James Mattus in Boston, the team is known for its deep expertise in M&A, IPOs, private equity, and fiduciary issues under ERISA. The firm is a go-to advisor for financial institutions, investment funds, and emerging growth companies, offering strategic counsel on equity arrangements, golden parachutes, and retirement plan structures.
Legal 500 redaktioneller Kommentar
Kernmandanten
- Astera Labs, Inc.
- ImmuNext, Inc.
- Human Immunology Biosciences (HI-Bio)
- Fusion Pharmaceuticals
- Century Therapeutics
- Deciphera
- Charlesbank Capital Partners, LLC
- AVROBIO
- Marlin Equity Partners
- Exabeam, Inc.
Highlight-Mandate
- Advised Astera Labs on the employee benefits and executive compensation aspects of its $774 million initial public offering.
- Advised Human Immunology Biosciences (HI-Bio™) on the employee benefits and executive compensation aspects of its $1.15 billion acquisition by Biogen.
- Advised TowerBrook Capital Partners L.P. on the employee benefits and executive compensation aspects of its majority equity investment inLiftWerx Holdings Inc.
Anwält*innen
Praxisleitung
Patrick Menasco, James Mattus
Weitere Kernanwält*innen
Lynda Galligan; Natascha George; Monica Patel